INPP5D and Alzheimer disease: Given that compound 1 provides a platform for a new class of SHIP1 activators with a potentially new binding mode and interesting biological effects in AD models, synthetic studies were initiated with two primary objectives: (1) determine key structure–activity relationships and (2) find molecules less prone to oxidative degradation.